Qiagen debuts QIA Agent and integrates NVIDIA BioNeMo for AI drug discovery
QGEN•Qiagen launched QIA Agent globally, an AI-powered digital assistant that streamlines experiment planning, product selection, technical guidance and ordering via a conversational interface. Qiagen’s Digital Insights division will integrate NVIDIA’s accelerated computing and BioNeMo platform to enhance AI-driven drug discovery from target identification to biomarker research.
1. Global Launch of QIA Agent
Qiagen has globally launched QIA Agent, an AI-powered digital assistant that provides conversational support for experiment planning, product selection, access to technical resources and order management across its Sample to Insight workflows. The tool aims to reduce complexity for researchers by consolidating multiple tasks into a single interface and leveraging Qiagen’s existing data and product catalog.
2. Partnership with NVIDIA for AI Drug Discovery
Qiagen’s Digital Insights bioinformatics division will integrate NVIDIA’s accelerated computing and BioNeMo platform to advance AI-driven drug discovery. This collaboration applies graph-based AI over curated biomedical knowledge graphs to accelerate target identification, biomarker discovery and hypothesis generation, with pilot programmes available to select pharmaceutical and biotechnology partners prior to a broader rollout.
